Molecular diagnosis of genetic iron-overload disorders

References

• Brissot P, Troadec MB, Bardou-Jacquet E et al. Current approach to hemochromatosis. Blood Rev.22(4), 195–210 (2008).
   PubMedGoogle Scholar
• Wallace DF, Subramaniam VN. Non-HFE haemochromatosis. World J. Gastroenterol.13(35), 4690–4698 (2007).
   PubMedGoogle Scholar
• Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet.13(4), 399–408 (1996).
   PubMed Web of Science ®Google Scholar
• Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat. Genet.41(4), 478–481 (2009).
   PubMed Web of Science ®Google Scholar
• Pantopoulos K. Function of the hemochromatosis protein HFE: lessons from animal models. World J. Gastroenterol.14(45), 6893–6901 (2008).
   PubMedGoogle Scholar
• Pigeon C, Ilyin G, Courselaud B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem.276(11), 7811–7819 (2001).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl Acad. Sci. USA98(15), 8780–8785 (2001).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis.29(3), 327–335 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol.122(2–3), 78–86 (2009).
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest.117(7), 1933–1939 (2007).
   PubMed Web of Science ®Google Scholar
• Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin1 expression independently of Hfe, transferrin receptor 2. Proc. Natl Acad. Sci. USA103(27), 10289–10293 (2006).
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet.38, 531–539 (2006).
   PubMed Web of Science ®Google Scholar
• Kautz L, Meynard D, Besson-Fournier C et al. BMP/SMAD signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood114(12), 2515–2520 (2009).
   PubMed Web of Science ®Google Scholar
• Corradini E, Garuti C, Montosi G et al. Bone morphogenetic protein signaling is impaired in a Hfe knockout mouse model of hemochromatosis. Gastroenterology137(4), 1489–1497 (2009).
   PubMed Web of Science ®Google Scholar
• Ramey G, Deschemin JC, Vaulont S. Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica94(6), 765–772 (2009).
   PubMedGoogle Scholar
• Hershko C, Peto TE. Non-transferrin plasma iron. Br. J. Haematol.66(2), 149–151 (1987).
   PubMed Web of Science ®Google Scholar
• Brissot P, Wright TL, Ma WL, Weisiger RA. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J. Clin. Invest.76(4), 1463–1470 (1985).
   PubMed Web of Science ®Google Scholar
• Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood102(7), 2670–2677 (2003).
   PubMed Web of Science ®Google Scholar
• Le Lan C, Loreal O, Cohen T et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood105(11), 4527–4531 (2005).
   PubMed Web of Science ®Google Scholar
• Brissot P. Haemochromatoses. New understanding, new treatments. Gastroenterol. Clin. Biol.33(8–9), 859–867 (2009).
   PubMedGoogle Scholar
• Distante S, Berg JP, Lande K, Haug E, Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut47(4), 575–579 (2000).
   PubMed Web of Science ®Google Scholar
• Adams PC, Reboussin DM, Barton JC et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med.352(17), 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• McLaren GD, McLaren CE, Adams PC et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can. J. Gastroenterol.22(11), 923–930 (2008).
   PubMedGoogle Scholar
• Allen KJ, Gurrin LC, Constantine CC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med.358(3), 221–230 (2008).
   PubMed Web of Science ®Google Scholar
• Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J. Hepatol.33(3), 485–504 (2000).
   PubMed Web of Science ®Google Scholar
• Bensaid M, Fruchon S, Mazeres C, Bahram S, Roth MP, Coppin H. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology126(5), 1400–1408 (2004).
   PubMedGoogle Scholar
• Millet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway module HFE hemochromatosis penetrance. Am. J. Human Genet.81, 799–807 (2007).
   PubMedGoogle Scholar
• Milet J, Le Gac G, Scotet V et al. A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: a follow-up study. Blood Cells Mol. Dis.44(1), 34–37 (2009).
   PubMedGoogle Scholar
• Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology110(4), 1107–1119 (1996).
   PubMed Web of Science ®Google Scholar
• Falize L, Guillygomarc’h A, Perrin M et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology44(2), 472–477 (2006).
   PubMed Web of Science ®Google Scholar
• Camaschella C, Poggiali E. Towards explaining “unexplained hyperferritinemia”. Haematologica94(3), 307–309 (2009).
   PubMed Web of Science ®Google Scholar
• Aguilar Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am. J. Gastroenterol.100, 1185–1194 (2005).
   PubMedGoogle Scholar
• Gandon Y, Olivié D, Guyader D et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet33, 338–343 (2004).
   Google Scholar
• St Pierre TG, Clark PR, Chua-anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood105(2), 855–861 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart. J.22(23), 2171–2179 (2001).
   PubMed Web of Science ®Google Scholar
• Jouanolle AM, Fergelot P, Gandon G, Yaouanq J, Le Gall JY, David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum. Genet.100(5–6), 544–547 (1997).
   PubMedGoogle Scholar
• Gurrin LC, Bertalli NA, Dalton GW et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology50(1), 94–101 (2009).
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Orii KO, Fleming RE et al. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Proc. Natl Acad. Sci. USA100(26), 15788–15793 (2003).
   PubMed Web of Science ®Google Scholar
• Zoller H, Cox TM. Hemochromatosis: genetic testing and clinical practice. Clin. Gastroenterol. Hepatol.3(10), 945–958 (2005).
   PubMed Web of Science ®Google Scholar
• Kinkely SM, Brown BD, Lyng AT et al. Absence of overt iron overload in two individuals compound heterozygotes for a 22 base pair deletion of exon 2 and the C282Y missense mutation of the HFE gene. Clin. Genet.63(2), 163–165 (2003).
   PubMedGoogle Scholar
• Barton JC, West C, Lee PL, Beutler E. A previously undescribed frameshift deletion mutation of HFE (c.del277; G93fs) associated with hemochromatosis and iron overload in a C282Y heterozygote. Clin. Genet.66(3), 214–216 (2004).
   PubMedGoogle Scholar
• Le Gac G, Congiu R, Gourlaouen I, Cau M, Ferec C, Melis MA. Homozygous deletion of HFE is the common cause of hemochromatosis in Sardinia. Haematologica95(4), 685–687 (2009).
   PubMedGoogle Scholar
• Merryweather-Clarke AT, Cadet E, Bomford A et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum. Mol. Genet.12(17), 2241–2247 (2003).
   PubMed Web of Science ®Google Scholar
• Le Gac G, Gourlaouen I, Ronsin C et al. Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype. Blood112(13), 5238–5240 (2008).
   PubMedGoogle Scholar
• Pelucchi S, Mariani R, Bertola F, Arosio C, Piperno A. Homozygous deletion of HFE: the Sardinian hemochromatosis? Blood113(16), 3886 (2009).
   PubMed Web of Science ®Google Scholar
• Cukjati M, Koren S, Curin Serbec V, Vidan-Jeras B, Rupreht R. A novel homozygous frameshift deletion c.471del of HFE associated with hemochromatosis. Clin. Genet.71(4), 350–353 (2007).
   PubMedGoogle Scholar
• Pointon JJ, Lok CY, Shearman JD et al. A novel HFE mutation (c.del478) results in nonsense-mediated decay of the mutant transcript in a hemochromatosis patient. Blood Cells Mol. Dis.43(2), 194–198 (2009).
   PubMedGoogle Scholar
• Papanikolaou G, Samuels ME, Ludwig EH et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet.36(1), 77–82 (2004).
   PubMed Web of Science ®Google Scholar
• Roetto A, Papanikolaou G, Politou M et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet.33(1), 21–22 (2003).
   PubMed Web of Science ®Google Scholar
• Gehrke SG, Pietrangelo A, Kascak M et al. HJV gene mutations in European patients with juvenile hemochromatosis. Clin. Genet.67(5), 425–428 (2005).
   PubMed Web of Science ®Google Scholar
• Lok CY, Merryweather-Clarke AT, Viprakasit V et al. Iron overload in the Asian community. Blood114(1), 20–25 (2009).
   PubMedGoogle Scholar
• Matthes T, Aguilar-Martinez P, Pizzi-Bosman L et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5´-UTR of the HAMP gene. Blood104(7), 2181–2183 (2004).
   PubMedGoogle Scholar
• Lanzara C, Roetto A, Daraio F et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood103(11), 4317–4321 (2004).
   PubMed Web of Science ®Google Scholar
• Nagayoshi Y, Nakayama M, Suzuki S et al. A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur. J. Heart Fail.10(10), 1001–1006 (2008).
   PubMedGoogle Scholar
• Brakensiek K, Fegbeutel C, Malzer M, Struber M, Kreipe H, Stuhrmann M. Juvenile hemochromatosis due to homozygosity for the G320V mutation in the HJV gene with fatal outcome. Clin. Genet.76(5), 493–495 (2009).
   PubMedGoogle Scholar
• Murugan RC, Lee PL, Kalavar MR, Barton JC. Early age-of-onset iron overload and homozygosity for the novel hemojuvelin mutation HJV R54X (exon 3; c.160A-->T) in an African–American male of West Indies descent. Clin. Genet.74(1), 88–92 (2008).
   PubMedGoogle Scholar
• Janosi A, Andrikovics H, Vas K et al. Homozygosity for a novel nonsense mutation (G66X) of the HJV gene causes severe juvenile hemochromatosis with fatal cardiomyopathy. Blood105(1), 432 (2005).
   PubMedGoogle Scholar
• Koyama C, Hayashi H, Wakusawa S et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J. Hepatol.43(4), 740–742 (2005).
   PubMed Web of Science ®Google Scholar
• Filali M, Le Jeunne C, Durand E et al. Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. Blood Cells Mol. Dis.33(2), 120–124 (2004).
   PubMedGoogle Scholar
• Aguilar-Martinez P, Lok CY, Cunat S, Cadet E, Robson K, Rochette J. Juvenile hemochromatosis caused by a novel combination of hemojuvelin G320V/R176C mutations in a 5-year old girl. Haematologica92(3), 421–422 (2007).
   PubMedGoogle Scholar
• Daraio F, Ryan E, Gleeson F, Roetto A, Crowe J, Camaschella C. Juvenile hemochromatosis due to G320V/Q116X compound heterozygosity of hemojuvelin in an Irish patient. Blood Cells Mol. Dis.35(2), 174–176 (2005).
   PubMedGoogle Scholar
• Island ML, Jouanolle AM, Mosser A et al. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica94(5), 720–724 (2009).
   PubMed Web of Science ®Google Scholar
• Charbonnier F, Raux G, Wang Q et al. Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res.60(11), 2760–2763 (2000).
   PubMed Web of Science ®Google Scholar
• Dehainault C, Lauge A, Caux-Moncoutier V et al. Multiplex PCR/liquid chromatography assay for detection of gene rearrangements: application to RB1 gene. Nucleic Acids Res.32(18), e139 (2004).
   PubMedGoogle Scholar
• Wallace DF, Summerville L, Subramaniam VN. Targeted disruption of the hepatic transferrin receptor 2 gene in mice leads to iron overload. Gastroenterology132(1), 301–310 (2007).
   PubMedGoogle Scholar
• Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood105(4), 1803–1806 (2005).
   PubMed Web of Science ®Google Scholar
• Kawabata H, Fleming RE, Gui D et al. Expression of hepcidin is down-regulated in TFR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood105(1), 376–381 (2005).
   PubMed Web of Science ®Google Scholar
• Camaschella C, Roetto A, Cali A et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat. Genet.25(1), 14–15 (2000).
   PubMed Web of Science ®Google Scholar
• Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br. J. Haematol.125(5), 674–678 (2004).
   PubMed Web of Science ®Google Scholar
• Roetto A, Totaro A, Piperno A et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood97(9), 2555–2560 (2001).
   PubMed Web of Science ®Google Scholar
• Girelli D, Bozzini C, Roetto A et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology122(5), 1295–1302 (2002).
   PubMed Web of Science ®Google Scholar
• Hattori A, Wakusawa S, Hayashi H et al. AVAQ 594–597 deletion of the TFR2 gene in a Japanese family with hemochromatosis. Hepatol. Res.26(2), 154–156 (2003).
   PubMedGoogle Scholar
• Mattman A, Huntsman D, Lockitch G et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood100(3), 1075–1077 (2002).
   PubMedGoogle Scholar
• Koyama C, Wakusawa S, Hayashi H et al. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica90(3), 302–307 (2005).
   PubMedGoogle Scholar
• Biasiotto G, Camaschella C, Forni GL, Polotti A, Zecchina G, Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica93(2), 309–310 (2008).
   PubMedGoogle Scholar
• Hsiao PJ, Tsai KB, Shin SJ et al. A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis. J. Hepatol.47(2), 303–306 (2007).
   PubMedGoogle Scholar
• Pelucchi S, Mariani R, Trombini P et al. Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2. Haematologica94(2), 276–279 (2009).
   PubMed Web of Science ®Google Scholar
• Lee PL, Barton JC. Hemochromatosis and severe iron overload associated with compound heterozygosity for TFR2 R455Q and two novel mutations TFR2 R396X and G792R. Acta. Haematol.115(1–2), 102–105 (2006).
   PubMedGoogle Scholar
• Donovan A, Lima CA, Pinkus JL et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab.1(3), 191–200 (2005).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science306(5704), 2090–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Pietrangelo A. The ferroportin disease. Blood Cells Mol. Dis.32, 131–138 (2004).
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, Nemeth E et al. The molecular basis of ferroportin-linked hemochromatosis. Proc. Natl Acad. Sci. USA102(25), 8955–8960 (2005).
   PubMed Web of Science ®Google Scholar
• Montosi G, Donovan A, Totaro A et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J. Clin. Invest.108(4), 619–623 (2001).
   PubMed Web of Science ®Google Scholar
• Njajou OT, Vaessen N, Joosse M et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat. Genet.28(3), 213–214 (2001).
   PubMed Web of Science ®Google Scholar
• Sham RL, Phatak PD, Nemeth E, Ganz T. Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood114(2), 493–494 (2009).
   PubMedGoogle Scholar
• Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol. Dis.34(2), 157–161 (2005).
   PubMed Web of Science ®Google Scholar
• Drakesmith H, Schimanski LM, Ormerod E et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood106, 1092–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am. J. Physiol. Cell Physiol.298(1), C75–C84 (2010).
   PubMedGoogle Scholar
• Fernandes A, Preza GC, Phung Y et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood114(2), 437–443 (2009).
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, di Patti MC et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J.26(12), 2823–2831 (2007).
   PubMed Web of Science ®Google Scholar
• Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals16(1), 205–213 (2003).
   PubMed Web of Science ®Google Scholar
• Loreal O, Turlin B, Pigeon C et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J. Hepatol.36(6), 851–856 (2002).
   PubMed Web of Science ®Google Scholar
• Fasano A, Colosimo C, Miyajima H, Tonali PA, Re TJ, Bentivoglio AR. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov. Disord.23(5), 751–755 (2008).
   PubMed Web of Science ®Google Scholar
• Yazaki M, Yoshida K, Nakamura A et al. A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. J. Neurol. Sci.156(1), 30–34 (1998).
   PubMedGoogle Scholar
• McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur. Neurol.60(4), 200–205 (2008).
   PubMedGoogle Scholar
• Knisely AS, Gelbart T, Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood104(8), 2607 (2004).
   PubMedGoogle Scholar
• Iolascon A, Camaschella C, Pospisilova D, Piscopo C, Tchernia G, Beaumont C. Natural history of recessive inheritance of DMT1 mutations. J. Pediatr.152(1), 136–139 (2008).
   PubMed Web of Science ®Google Scholar